Zenas BioPharma, Inc. (ZBIO) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$240.4M

EPS$-8.44

Market Cap$1.2B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Leon Moulder

CEO & Executive Director

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcÎ³RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Founded: 2019
Employees: 167

⚡

Core Efficiency

ROE?

-99.30%

ROA?

-62.67%

D/E Ratio?

0.58

📊

Profitability Ratios

Current Ratio?

5.61

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 27, 2026 (in 109 days)

Annual Report (10-K) — Based on filing pattern

Jul 27, 2026

Predicted10-K

Mar 16, 2026

10-KQ4 202516d after period end

Nov 12, 2025

10-QQ3 202512d after period end

Aug 12, 2025

10-QQ2 202512d after period end

May 15, 2025

10-QQ1 202515d after period end

Mar 11, 2025

10-KQ4 202411d after period end

Nov 12, 2024

10-QQ3 202412d after period end

Loading company sections...

Zenas BioPharma, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness